CSF3 and breast carcinoma: Thus, the suboptimal use of a daily G-CSF may represent an increased cost per patient compared with pegfilgrastim, as demonstrated by a recent pharmacoeconomic model in breast cancer patients at high risk of febrile neutropenia (Cámara et al. 2008).